Patents Assigned to Aerpio Therapeutics Inc.
-
Patent number: 10562854Abstract: Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1?), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.Type: GrantFiled: February 20, 2018Date of Patent: February 18, 2020Assignee: AERPIO THERAPEUTICS, INC.Inventors: Joseph H. Gardner, Robert Shalwitz, Shengde Wu
-
Patent number: 10329357Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.Type: GrantFiled: March 20, 2017Date of Patent: June 25, 2019Assignee: AERPIO THERAPEUTICS, INC.Inventors: Kevin Peters, Robert Shalwitz
-
Patent number: 10253094Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.Type: GrantFiled: July 19, 2017Date of Patent: April 9, 2019Assignee: Aerpio Therapeutics, Inc.Inventors: Kevin Peters, Michael Allen Flynn
-
Patent number: 10220048Abstract: Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.Type: GrantFiled: November 18, 2016Date of Patent: March 5, 2019Assignee: AERPIO THERAPEUTICS, INC.Inventors: Kevin Peters, Robert Shalwitz
-
Patent number: 10150811Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.Type: GrantFiled: February 21, 2017Date of Patent: December 11, 2018Assignee: AERPIO THERAPEUTICS, INC.Inventors: Kevin Peters, Robert Shalwitz
-
Patent number: 9994560Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.Type: GrantFiled: March 13, 2015Date of Patent: June 12, 2018Assignee: AERPIO THERAPEUTICS, INC.Inventors: John Janusz, James Copp, Kevin Peters
-
Patent number: 9949956Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.Type: GrantFiled: September 24, 2015Date of Patent: April 24, 2018Assignee: Aerpio Therapeutics, Inc.Inventors: Robert Shalwitz, Kevin Gene Peters
-
Patent number: 9926367Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.Type: GrantFiled: February 10, 2017Date of Patent: March 27, 2018Assignee: AERPIO THERAPEUTICS, INC.Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
-
Patent number: 9795594Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.Type: GrantFiled: February 5, 2016Date of Patent: October 24, 2017Assignee: AERPIO THERAPEUTICS, INC.Inventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
-
Patent number: 9539245Abstract: The present invention relates to combination therapies comprising at least one activator of Tie-2 and immunotherapies that target immune checkpoints. Combination therapies of the disclosure can provide therapeutic effects not obtained with singly-administered immunotherapies. Combination therapies can be used to increase the therapeutic efficacy of an immunotherapy, to provide lower dosages of an immunotherapy being administered, to lower a toxicity of an immunotherapy, or to manage a side effect of an immunotherapy.Type: GrantFiled: August 6, 2015Date of Patent: January 10, 2017Assignee: AERPIO THERAPEUTICS, INC.Inventor: Kevin Peters
-
Patent number: 9540326Abstract: Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1?), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.Type: GrantFiled: April 16, 2015Date of Patent: January 10, 2017Assignee: AERPIO THERAPEUTICS, INC.Inventors: Joseph H. Gardner, Robert Shalwitz
-
Patent number: 9440963Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.Type: GrantFiled: March 14, 2014Date of Patent: September 13, 2016Assignee: AERPIO THERAPEUTICS, INC.Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
-
Patent number: 9388135Abstract: Disclosed herein is a process for preparing N-benzyl-3-hydroxypyridin-2-(1H)-ones that are substituted at the pyridine ring 4-position with a 4-carbamoylpiperazin-1-yl moiety.Type: GrantFiled: February 18, 2015Date of Patent: July 12, 2016Assignee: AERPIO THERAPEUTICS, INC.Inventors: Dino Alberico, Craig Dixon, Boris Gorin, Jan Oudenes
-
Patent number: 9284285Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.Type: GrantFiled: April 14, 2014Date of Patent: March 15, 2016Assignee: AERPIO THERAPEUTICS, INC.Inventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
-
Patent number: 9278930Abstract: Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1?) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1? prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1?.Type: GrantFiled: February 22, 2015Date of Patent: March 8, 2016Assignee: AERPIO THERAPEUTICS, INC.Inventors: Robert Shalwitz, Joseph H. Gardner
-
Patent number: 9174950Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.Type: GrantFiled: May 8, 2014Date of Patent: November 3, 2015Assignee: Aerpio Therapeutics, Inc.Inventors: Robert Shalwitz, Kevin Gene Peters
-
Patent number: 9126958Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.Type: GrantFiled: December 12, 2014Date of Patent: September 8, 2015Assignee: AERPIO THERAPEUTICS, INC.Inventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
-
Patent number: 9096555Abstract: Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, inflammatory bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage.Type: GrantFiled: December 21, 2012Date of Patent: August 4, 2015Assignee: AERPIO THERAPEUTICS, INC.Inventors: Robert Shalwitz, Kevin Gene Peters
-
Patent number: 9045495Abstract: Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1?), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.Type: GrantFiled: February 15, 2013Date of Patent: June 2, 2015Assignee: AERPIO THERAPEUTICS INC.Inventors: Joseph H. Gardner, Robert Shalwitz
-
Patent number: RE46592Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.Type: GrantFiled: November 11, 2015Date of Patent: October 31, 2017Assignee: Aerpio Therapeutics, Inc.Inventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier